Many hurdles to overcome before human trials can start
CDC/UnsplashScientists have demonstrated the potential of CRISPR-Cas9 technology to remove the HIV genome from the DNA of infected cells. They have also identified some of the consequences of doing so and begun to investigate how these side-effects may be mitigated.
In one study, Dr Michele Lai and colleagues at the University of Pisa demonstrated the capacity of CRISPR-Cas9 to remove HIV genetic material from infected cells but also investigated whether the excised sections of DNA may reintegrate and start replicating again.
In another, Dr Jonathan Herskovitz and team at the University of Nebraska showed that when CRISPR-Cas9 is manipulated to target multiple sites at two of HIV’s most important genes, viral replication in infected cells almost completely stopped – with no immediately obvious damage to cellular DNA.
Read the full story at Aidsmap.
Source : Aidsmap
Related HIV and Co-Infections News
-
[Press release] Gilead and Merck announce positive topline results from two Phase 3 studies evaluating islatravir/lenacapavir, an oral once-weekly HIV treatment
-
aidsmap: Switching to an integrase inhibitor can raise diabetes risk in people with HIV
-
TheBodyPro: Can long-acting regimens solve virologic failure in heavily treatment-experienced people with HIV?
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.